Wealth Enhancement Advisory Services, LLC Zentalis Pharmaceuticals, Inc. Transaction History
Wealth Enhancement Advisory Services, LLC
- $44.5 Billion
- Q3 2024
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 67,893 shares of ZNTL stock, worth $235,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,893
Previous 47,045
44.32%
Holding current value
$235,588
Previous $192,000
29.69%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
68MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$48.4 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$29.7 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$16.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$16 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$10.8 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $198M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...